Ocrelizumab for Psychosis by Autoimmunity
Ocrelizumab for Psychosis by Autoimmunity
Recruiting · NCT03971487 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ocrelizumab for Psychosis by Autoimmunity | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 1 / Phase 2 | 2026-04-01 | NCT03971487 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| The Methodist Hospital Research Institute | 124 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Houston Methodist Research Institute | Houston | United States | 32 |